Toshiya Kamiyama, Hideki Yokoo, Jun‐Ichi Furukawa, Masaki Kurogochi, Tomoaki Togashi, Nobuaki Miura, Kazuaki Nakanishi, Hirofumi Kamachi, Tatsuhiko Kakisaka, Yosuke Tsuruga, Masato Fujiyoshi, Akinobu Taketomi, Shin‐Ichiro Nishimura, Satoru Todo – 15 January 2013 – The altered N‐glycosylation of glycoproteins has been suggested to play an important role in the behavior of malignant cells. Using glycomics technology, we attempted to determine the specific and detailed N‐glycan profile for hepatocellular carcinoma (HCC) and investigate the prognostic capabilities.

Justin R. Henning, Christopher S. Graffeo, Adeel Rehman, Nina C. Fallon, Constantinos P. Zambirinis, Atsuo Ochi, Rocky Barilla, Mohsin Jamal, Michael Deutsch, Stephanie Greco, Melvin Ego‐Osuala, Usama Bin‐Saeed, Raghavendra S. Rao, Sana Badar, Juan P. Quesada, Devrim Acehan, George Miller – 15 January 2013 – Nonalcoholic steatohepatitis (NASH) is the most common etiology of chronic liver dysfunction in the United States and can progress to cirrhosis and liver failure. Inflammatory insult resulting from fatty infiltration of the liver is central to disease pathogenesis.

Katharina Esser‐Nobis, Inés Romero‐Brey, Tom M. Ganten, Jérôme Gouttenoire, Christian Harak, Rahel Klein, Peter Schemmer, Marco Binder, Paul Schnitzler, Darius Moradpour, Ralf Bartenschlager, Stephen J. Polyak, Wolfgang Stremmel, François Penin, Christoph Eisenbach, Volker Lohmann – 15 January 2013 – Intravenous silibinin (SIL) is an approved therapeutic that has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C virus (HCV) infection in some patients even in monotherapy.

Ming‐Lung Yu, Chuan‐Mo Lee, Chi‐Ling Chen, Wan‐Long Chuang, Sheng‐Nan Lu, Chen‐Hua Liu, Shun‐Sheng Wu, Li‐Ying Liao, Hsing‐Tao Kuo, You‐Chen Chao, Shui‐Yi Tung, Sien‐Sing Yang, Jia‐Horng Kao, Wei‐Wen Su, Chih‐Lin Lin, Hung‐Chih Yang, Pei‐Jer Chen, Ding‐Shinn Chen, Chun‐Jen Liu, for the Taiwan Liver‐Net Consortium – 15 January 2013 – Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients.

Wei Wei, Juan Hou, Olivia Alder, Xin Ye, Sam Lee, Rebecca Cullum, Andy Chu, Yongjun Zhao, Stephanie M. Warner, Darryl A. Knight, Decheng Yang, Steven J.M. Jones, Marco A. Marra, Pamela A. Hoodless – 12 January 2013 – MicroRNAs (miRNAs) are recently discovered small RNA molecules that regulate developmental processes, such as proliferation, differentiation, and apoptosis; however, the identity of miRNAs and their functions during liver development are largely unknown.

Jean‐François Dufour – 12 January 2013

Sasan Roayaie, Josep Llovet, Myron Schwartz, Vincenzo Mazzaferro – 12 January 2013

Xiao‐Yong Huang, Ai‐Wu Ke, Guo‐Ming Shi, Xin Zhang, Chi Zhang, Ying‐Hong Shi, Xiao‐Ying Wang, Zhen‐Bin Ding, Yong‐Sheng Xiao, Jun Yan, Shuang‐Jian Qiu, Jia Fan, Jian Zhou – 12 January 2013 – The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular pathogenesis remains incompletely defined in HCC. Here we report that increased expression of αB‐Crystallin in human HCC predicts poor survival and disease recurrence after surgery.

David Fuks, Francois Durand, Jacques Belghiti – 12 January 2013

Simon Hohenester, Ulrich Beuers, Juan F. Medina, Ronald P. Oude Elferink – 12 January 2013